PD1 monotherapy reigns supreme in adjuvant melanoma…but for how long?

The results of CheckMate-238 led to the original FDA approval of anti-PD1 therapy in high-risk, resectable melanoma. In this CCR Translations, we discuss the 5-year update of this pivotal trial and contextualize its results in the face of limited survival data, neoadjuvant therapy, next-generation b...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2023-09, Vol.29 (17), p.3253-3255
Main Authors: Augustin, Ryan C., Luke, Jason J.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The results of CheckMate-238 led to the original FDA approval of anti-PD1 therapy in high-risk, resectable melanoma. In this CCR Translations, we discuss the 5-year update of this pivotal trial and contextualize its results in the face of limited survival data, neoadjuvant therapy, next-generation biomarkers, and novel immunotherapy combinations.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-23-1194